VEGFA and wet macular degeneration: Later, Lucentis® (ranibizumab, by Genentech/Novartis), a humanised antibody fragment that blocks the receptor binding domain of all isoforms of VEGF-A, and Eylea® (aflibercept, by Regeneron/Bayer), a recombinant fusion protein with higher affinity for VEGF-A, became established treatments for wet AMD [16,23,24].